The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...

More than two million patients face virtually no treatment options or are forced to pay exorbitant prices on black market, ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

The table below is a review of notable updates ... inhibitor Treatment of adults with recurrent low-grade serous ovarian cancer who received at least 1 prior systemic therapy and have a KRAS ...

Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant ...

A range of current precision oncology clinical trials are reliant on customized, targeted NGS-panel assays in order to ...

After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking off 2025 with a return to the dealmaking table. Under a new licensing ...

It turns out that Róisín received a life-changing diagnosis of breast cancer in October 2023 and in this very personal podcast she talks to Kathy Sheridan about how events unfolded – how she was told ...

Cancer incidence continues to rise for many common cancers—especially for women. The incidence rate for women younger than 50 ...

The journal also reports on exciting new developments being made in diagnosis, surgery, radiotherapy, drug discovery ... Prostate Cancer and Prostatic Diseases now provides its latest table ...

In this article, I employ AI to rank 19 repurposed drugs and supplements by effectiveness against metastatic cancer. To add ...